Bli medlem
Bli medlem

Du är här


DORO AB: Redeye: New ailments revealed in Doro

We had expected a recovery in Q3 and a sales growth of 10 percent but
instead sales fell -2 percent. In North America, Doro has failed to
introduce a 4G phone in time, meaning the weakness in US & Canada
will continue into H2'18. Our EBIT estimates for 2018-2019 drop -40
percent and our base case falls with SEK 13 per share.

Read more in the Research Update by Viktor Westman at:

Start following companies at Redeye to receive the latest equity
research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment


Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.